The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA RESOURCE LIBRARY

Access useful forms, tools, and documents for your practice below

Explore everything from OTEZLA MOA to patient experiences, as well as the current treatment and management landscape
  • Opening frame for a video that reviews the mechanism of action of OTEZLA®
    OTEZLA Mechanism of Action
  • Opening frame for a video that reviews the involvement of PDE4 in psoriasis
    The Landscape of Psoriasis
  • Opening frame of the video titled, "The Role of PDE4 in Psoriatic Disease and the Effect of PDE4 Inhibition," in which Dr. Peter H. Schafer reviews the effect of PDE4 inhibition in psoriatic disease
    OTEZLA Expert Presentation
  • Opening frame of a video in which a person describes the impact of plaque psoriasis on her life and shares her experience with OTEZLA® and other treatments. Please see full Important Safety Information.
    Patient Story - Jo Anne
  • Opening frame of a video in which a person describes the impact of plaque psoriasis on his life and shares his experience with OTEZLA® and other treatments. Please see full Important Safety Information.
    Patient Story - Lesly
  • Opening frame of a video in which a person describes the impact of plaque psoriasis on her life and shares her experience with OTEZLA® and other treatments. Please see full Important Safety Information.
    Patient Story - Tarlan
  • Opening frame of a video in which experts review the results of the MAPP survey about unmet needs of people with psoriasis
    MAPP Expert Opinions
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.